We are live on
!
Find out more
PM
Prosight Management Portfolio holdings
AUM
$580M
1-Year Est. Return
29.81%
This Fund
S&P 500
This Quarter
Est. Return
+15.1%
1 Year Est. Return
+29.81%
3 Year Est. Return
+39.55%
5 Year Est. Return
-6.93%
10 Year Est. Return
–
AUM
$187M
AUM Growth
+$59.7M
(+47%)
Cap. Flow
+$48.5M
Cap. Flow
% of AUM
25.99%
Top 10 Holdings %
Top 10 Hldgs %
63.01%
Holding
43
New
19
Increased
10
Reduced
9
Closed
5
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$21.2M |
| 2 |
Alkermes
ALKS
|
+$13.1M |
| 3 |
Humana
HUM
|
+$6.23M |
| 4 |
Johnson & Johnson
JNJ
|
+$5.36M |
| 5 |
Oric Pharmaceuticals
ORIC
|
+$3.75M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ONEM
1Life Healthcare
ONEM
|
+$9.71M |
| 2 |
Prothena Corp
PRTA
|
+$7.24M |
| 3 |
Aldeyra Therapeutics
ALDX
|
+$4.65M |
| 4 |
KALV
KalVista Pharmaceuticals
KALV
|
+$4.06M |
| 5 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
+$3.25M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 97.15% |
| 2 | Miscellaneous | 2.53% |
| 3 | Industrials | 0.32% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Prothena Corp
PRTA
$423M
| $19.5M | 10.43% |
321,093
-228,907
| -42% | -$7.24M |
|
|
HZNP
2
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $18.8M | 10.05% |
+303,000
| New | +$21.2M |
|
|
LKFT
3
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.8B
| $17.3M | 9.25% |
405,000
+36,000
| +10% | +$1.84M |
|
|
KZR
4
DELISTED
Kezar Life Sciences
KZR
| $11.4M | 6.13% |
132,790
+6,521
| +5% | +$634K |
|
|
5
Alkermes
ALKS
$7.73B
| $11.2M | 6.01% |
+502,150
| New | +$13.1M |
|
|
ALBO
6
DELISTED
Albireo Pharma Inc
ALBO
| $9.51M | 5.09% |
491,244
+23,449
| +5% | +$485K |
|
7
MeiraGTx Holdings
MGTX
$1.23B
| $9.28M | 4.97% |
1,103,365
+117,147
| +12% | +$1.03M |
|
|
KALV
8
DELISTED
KalVista Pharmaceuticals
KALV
| $7.69M | 4.12% |
530,062
-290,690
| -35% | -$4.06M |
|
9
Charles River Laboratories
CRL
$13.1B
| $6.54M | 3.5% |
33,220
+5,720
| +21% | +$1.23M |
|
|
10
Aldeyra Therapeutics
ALDX
$82.6M
| $6.47M | 3.46% |
1,210,800
-775,083
| -39% | -$4.65M |
|
|
11
Humana
HUM
$46.2B
| $6.21M | 3.33% |
+12,800
| New | +$6.23M |
|
12
Mirum Pharmaceuticals
MIRM
$6.32B
| $5.99M | 3.21% |
285,000
+123,473
| +76% | +$2.97M |
|
13
Tenet Healthcare
THC
$21.4B
| $5.26M | 2.82% |
102,000
+51,300
| +101% | +$3.04M |
|
|
14
Johnson & Johnson
JNJ
$644B
| $5.18M | 2.77% |
+31,704
| New | +$5.36M |
|
15
QuidelOrtho
QDEL
$739M
| $4.5M | 2.41% |
62,900
+16,324
| +35% | +$1.46M |
|
16
Cue Biopharma
CUE
$248M
| $3.45M | 1.85% |
51,519
-3,664
| -7% | -$315K |
|
|
17
CALL
Prothena Corp
PRTA
$423M
| $3.22M | 1.72% |
+53,100
| New | +$1.68M |
|
18
Rocket Pharmaceuticals
RCKT
$382M
| $3.19M | 1.71% |
200,000
-76,802
| -28% | -$1.2M |
|
19
Shattuck Labs
STTK
$590M
| $3.03M | 1.62% |
1,120,776
+100,776
| +10% | +$378K |
|
|
20
Oric Pharmaceuticals
ORIC
$1.3B
| $3M | 1.61% |
+936,334
| New | +$3.75M |
|
21
Incyte
INCY
$25.3B
| $2.7M | 1.44% |
+40,450
| New | +$2.99M |
|
22
Omnicell
OMCL
$1.48B
| $2.67M | 1.43% |
+30,700
| New | +$3.23M |
|
23
Avantor
AVTR
$10.6B
| $2.4M | 1.29% |
+122,668
| New | +$3.29M |
|
24
Baxter International
BAX
$12.2B
| $2.1M | 1.13% |
+39,000
| New | +$2.35M |
|
25
Rhythm Pharmaceuticals
RYTM
$6.75B
| $1.96M | 1.05% |
+80,000
| New | +$1.49M |
|
Similar funds
SC
CCWM
CMA
RIS
MFS
GFI
PWM
CA
Prosight Management's Q3 2022 Portfolio in Review
As of Q3 2022, Prosight Management held 43 positions worth $187M, up 47% from $127M the previous quarter. Its ten largest holdings account for 63% of the portfolio.
Prosight Management deployed $48.5M of net new capital in Q3 2022, opening 19 new positions and adding to 10 existing holdings. Its largest new stake was Horizon Therapeutics Public Limited Company Ordinary Shares: 303,000 shares worth $18.8M.
By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 97% a quarter earlier, followed by Miscellaneous and Industrials.
On the sell side, the largest reduction was 1Life Healthcare, an estimated $9.71M trimmed.
- Prosight Management's largest Q3 2022 buy was Horizon Therapeutics Public Limited Company Ordinary Shares: 303,000 shares worth $18.8M.
- Prosight Management added most to Tenet Healthcare in Q3 2022, an estimated $3.04M increase.
- Prosight Management's biggest Q3 2022 reduction was 1Life Healthcare, cutting an estimated $9.71M.
- Prosight Management fully exited Global Blood Therapeutics, Inc. in Q3 2022, selling an estimated $3.25M.
- Prosight Management's ten largest holdings make up 63% of its $187M portfolio in Q3 2022.
- Prosight Management opened 19 new positions and closed 5 in Q3 2022.
- Prosight Management's portfolio value rose 47% quarter-over-quarter to $187M.
Based on Prosight Management's 13F filing for Q3 2022, filed 14 Nov 2022.